🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Multi-Center Registry Cohort Study on Prognostic Factors and Prediction Model Construction in Aneurysmal SAH

Recruitingn/aAges 18 Years - anyAllSecond Affiliated Hospital of Nanchang University
NCT05738083 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

PROSAH-MPC, a collaborative research project among neurosurgical centers in China, focuses on aneurysmal subarachnoid hemorrhage (aSAH). Its aim is to identify prognostic factors and develop robust prediction models for complications, disability, and mortality in aSAH patients. By leveraging a large, multi-center, prospective cohort design, PROSAH-MPC aims to overcome limitations of past studies and provide a more comprehensive understanding of the disease.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Subarachnoid hemorrhage confirmed by computed tomography (CT); * Cerebral angiography (CTA) and digital subtraction angiography (DSA) examination confirming intracranial aneurysm rupture as the cause of the subarachnoid hemorrhage; * Blood routine, biochemical function, blood coagulation function, and craniocerebral CT performed within 24 hours of symptom onset; * Underwent aneurysm clipping by surgery or endovascular embolization within 72 hours after-onset. Exclusion Criteria: * Aneurysm rupture bleeding time exceeding 24 hours before hospital admission; * Incomplete image data or blood test information; * Long-term use of anticoagulant medications such as aspirin or warfarin; * Admitted to hospital with active infectious diseases; * long-term anticoagulant drugs such as aspirin, wave dimensions; * Presence of other intracranial vascular malformations.
💊

What it tests

  • Machine Leaning Models
📍

Where

1 site
The Second Affiliated Hospital of Nanchang University
Nanchang, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy